Instil Bio

The Cancer Immunotherapy Market 2025-2029 report forecasts significant growth in immuno-oncology therapeutics, highlighting technologies like CAR-T Cells and Checkpoint Inhibitors. It offers insights into market opportunities, key players, and the impact on healthcare, aiming to guide investment and strategic decisions.

SunAct Cancer Institute partners with Abgentil Biomedical to introduce CAR-T, TCR, and TIL therapies for solid tumours in India, aiming to provide advanced cancer treatment at affordable costs.

The non-small cell lung cancer market is driven by increasing NSCLC cases, uptake of immune checkpoint inhibitors, emerging premium therapies, and awareness of mutations. DelveInsight's report covers current treatment practices, emerging drugs, market share, and forecasted market size from 2019 to 2032 in 7MM. Key companies and therapies include EMD Serono, Merck, AstraZeneca, Bristol-Myers Squibb, and therapies like M1774, C-TIL051, and Osimertinib. FDA approvals for Opdivo and Tagrisso in 2024 highlight advancements in treatment.

This article is open access under a CC BY-NC-ND 4.0 license, allowing non-commercial use, sharing, and distribution with proper credit, but not adaptation. Third-party materials included unless otherwise stated. For adapted material, direct permission from the copyright holder is required.

Crescent Biopharma, a Paragon Therapeutics spinout, merges with GlycoMimetics, raising $200M to advance cancer immunotherapy targeting PD-1 and VEGF. Crescent aims to improve upon standard treatments like Keytruda, with initial data expected in 2026. The merger is set to close in Q2 2025.

Ottimo Pharma, backed by Medicxi and led by David Epstein, develops a bi-functional antibody targeting PD-1 and VEGFR2 to enhance cancer immunotherapy, aiming for clinical trials in 2025.

Bob Duggan's experimental cancer drug, ivonescimab, outperformed Keytruda in trials, boosting Summit Therapeutics' stock 700% and his net worth to $16 billion. The drug, now in 18 cancer trials, halved disease progression risk in advanced non-small-cell lung cancer patients.

August 2024 biopharma deals highlight trends in bispecific T-cell engagers, CD-19 targeting in autoimmune diseases, and Chinese biopharma innovation. Merck's $1.3B acquisition of Curon's CD3xCD19 BiTE CN201 reflects confidence in early trial outcomes and market enthusiasm for BiTEs. JPMorgan reports a 50% reduction in upfront payments since 2020, indicating a more back-loaded deal structure.